Since 1998, she has been working at Medical Oncology of Sun Yat-sen University Cancer Center and Good Clinical Practice (GCP) Center for New Anticancer Drugs. She is familiar with theories and techniques of molecular biology, capable of conducting experiment in cell biology, flow cytometry experiment and Western Blot; she has also mastered pharmacology experimental theories and techniques of pharmacology for anticancer drugs, and is able to inoculate tumor-bearing nude mice to test the anti-tumor efficacy of anticancer drugs. She has published more than 10 papers, and has led several research projects.

What is more, she has mastered biopharmaceutical analysis of drugs, proficient in operating atomic absorption spectroscopy instrument, high-performance liquid chromatography instrument, ultraviolet–visible spectrophotometer, microplate reader, RT-PCR instrument, and etc. She is familiar with national guidelines for GCP for trials on pharmaceutical products, including those for pharmacokinetic experiment, capable of establishing pharmacokinetic analysis methods and determining drug concentration; she can write plans and reports for pharmacokinetic experiments in Phase I/II/III clinical trials, and conduct preliminary analysis on pharmacokinetic-pharmacodynamic relationship, and the interaction of drugs.

Since 1998, she has led clinical pharmacokinetic study on several domestic and foreign Category I new drugs. Pharmacokinetic study of Phase I clinical trial of domestic drugs includes E10A (preparation for endostatin gene), ATV-TK/GCV, vinflunine, dicycloplatin, combretastatin, puquitinib mesylate, SM03 (CD22 monoclonal antibody), and fluorapacin; pharmacokinetic study of Phase I clinical trial of foreign drugs: ZD6474 and capxol; pharmacokinetic study of Phase III clinical trial: epothilone and etc.

Employed as a medical doctor by Sun Yat-Sen University Cancer Center and worked in medical oncology department and clinical trial center from 2003 after master degree of oncology until now. Got PhD degree in Sun-Yat sen University Cancer Center in 2011, mastered the key techniques of ELISA, RT-PCR, IHC, Cell Culture etc. During MD & PhD studies and clinical works, received professional training of researches on anti-cancer new drugs, and acquired the certificate of clinical trial training awarded by VIENNA School of CLINICAL RESEARCH, which is highly accredited. Shortly studied in The Chinese University of Hong Kong - Prince of Wales Hospital for clinical trial design and implementation in 2003. Participated in over 20 Phase I to IV clinical trials domestic or international, including INFORM study which had been selected as one of the top ten clinical oncology progress in 2012.

Dr. Hong received his M.D. from Sun Yat-Sen University of Medical Sciences (SUMS) in 1984, and worked for the department of design, measure, and evaluation (DME), SUMS. During 1987 to 1988, he finished a postgraduate training on medical decision in Case Western Reserve University, Cleveland, USA . Since 1991, Dr. Hong turned to department of NPC, Cancer Center, SUMS, as a lecturer, and took part in a series of the clinical investigations using the theory of DME. The development of new clinical staging system of NPC (1992 NPC staging), which was used widely later in China, was one of Dr. Hong contributions. The proposition of the idea of stratified multiple modality therapy of NPC according to different clinical stages was another project of Dr. Hong using the methods and viewpoints of DME.

Dr. Hong was promoted to be an associate professor in 1994. The clinical trails of stratified comprehensive therapy of NPC in an ongoing project under the charge of Dr. Hong. His main interest is multiple modality combined therpay of NPC.

Prof. Sun Jian has been working in Sun Yat-sen University Cancer Center since 2001. From September 2012 to April 2013, he was engaged as an external reviewer of Center for Drug Evaluation (CDE) in China Food and Drug Administration (CFDA). Now he serves as team leader of Quality Control Team at the GCP Center (a qualified national institution for clinical trial of new drugs), engaged in clinical trials of new drugs, quality control of clinical trial of in-vitro diagnostic reagents and medical devices, and management of institution’s offices.

Dr. Ji-Bin Li received his bachelor and master's degree from Sun Yat-sen University, and his doctorate degree from the Chinese University of Hong Kong. He joined Sun Yat-sen University Cancer Center in 2016, and served as a biostatistician in the department of Clinical Research, and was appointed as an associate researcher in 2021. He mainly conducts research in biostatistics in clinical trials and longitudinal studies, clinical epidemiology, and behaviors, psychology and well-being. He has obtained several research grants (e.g., National Natural Science Foundation, Guangdong Natural Science Foundation) as a principle investigator. Dr. Ji-Bin Li's academic output includes an authored book and book chapters on biostatistics and clinical epidemiology, and over 80 academic papers in peer-reviewed journals.

Statistical methods in clinical trials; longitudinal study design and statistical methods; clinical epidemiology; behaviors, psychology and well-being, and quality of life.

2012-2016, PhD, The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong

2009-2012, Master degree, School of Public Health, Sun Yat-sen University

2005-2009, Bachelor degree, Zhongshan school of Medicine, Sun Yat-sen University

1. Li JB#, Qiu ZY, Liu Z, Zhou Q, Feng LF, Li JD*, Zhang X*. Gender Differences in Factors Associated with Clinically Meaningful Weight Loss among Adults Who Were Overweight or Obese: A Population-Based Cohort Study. Obes Facts. 2021;14(1):108-120. (IF=3.514)

2. Li JB#, Guo SS#, Tang LQ, Guo L, Mo HY, Chen QY, Mai HQ*. Longitudinal Trend of Health-Related Quality of Life During Concurrent Chemoradiotherapy and Survival in Patients With Stage II-IVb Nasopharyngeal Carcinoma. Front Oncol. 2020 Oct 8;10:579292. (IF=4.848)

3. Li JB, Zhang JX, Hong MH. Methodology for Clinical Research [M]. Beijing: Science Press, 2020.

4. Li JB*, Wu AMS, Feng LF, Deng Y, Li JH, Chen YX, Mai JC, Mo PKH*, Lau JTF*. Classification of probable online social networking addiction: A latent profile analysis from a large-scale survey among Chinese adolescents. J Behav Addict. 2020 Aug 21; 9(3):698-708. (IF=5.143)

5. Wang XY#, Li JB#, Shi W#, Huang ZZ, Xia W, Huang JJ, Su YH, Wang SS, Shi YX, Bi XW*, Yuan ZY*. Efficacy of Moxifloxacin plus Treatment of Physician's Choice in Patients with Metastatic Breast Cancer. Oncologist. 2020 Oct; 25(10):e1439-e1445. (IF=5.025)

6. Li JB#, Wu Y, Gu D, Li H*, Zhang X*. Prevalence and temporal trends of presarcopenia metrics and related body composition measurements from the 1999 to 2006 NHANES. BMJ Open. 2020 Aug 5;10(8):e034495. (IF=2.496)

7. Li JB#*, Luo S#, Wong MCS, Li C, Feng LF, Peng JH, Li JH, Zhang X*. Longitudinal associations between BMI change and the risks of colorectal cancer incidence, cancer-relate and all-cause mortality among 81,388 older adults : BMI change and the risks of colorectal cancer incidence and mortality. BMC Cancer. 2019 Nov 11;19(1):1082. (IF=3.15)

8. Zhi-Qiang Wang#, Qi Mei#, Ji-Bin Li#, Rui You, You-Ping Liu, Rui Sun, Guang-Yuan Hu, Ming-Yuan Chen*, Yi-Jun Hua*. The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysis. BMC Cancer. 2019 Nov 19;19(1):1122. (IF=3.15)

9. Li JB*, Mo PKH, Lau JTF*, Su XF, Zhang X, Wu AMS, Mai JC, Chen YX. Online social networking addiction and depression: The results from a large-scale prospective cohort study in Chinese adolescents. J Behav Addict. 2018 Sep 1;7(3):686-696. (IF=5.143)

Updated March 2021 by International Office, Sun Yat-sen University Cancer Center